Matthew Buten - Dec 31, 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd. (BHVN)

Role
Chief Financial Officer
Signature
/s/ George Clark, Attorney-in-Fact
Stock symbol
BHVN
Transactions as of
Dec 31, 2021
Transactions value $
-$871,373
Form type
4
Date filed
1/4/2022, 08:30 PM
Previous filing
Dec 14, 2021
Next filing
Jan 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $0 +12.5K $0.00 12.5K Dec 31, 2021 Direct
transaction BHVN Common Shares Tax liability -$871K -6.32K -50.58% $137.81* 6.18K Dec 31, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Restricted Share Unit Award Options Exercise -12.5K -25% 37.5K Dec 31, 2021 Common Shares 12.5K Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the issuer in connection with mandatory share settlement to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F2 Each restricted share unit represents the contingent right to receive one common share of the issuer.
F3 The reporting person was granted 50,000 restricted share units on December 8, 2021. 12,500 of the restricted share units vested on December 8, 2021 and were subject to deferred settlement. The remainder vest in three equal installments on December 8, 2022, 2023 and 2024 subject to the reporting person's continued service with the issuer at each vesting date.
F4 Not applicable.